MOESM1 of Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

Additional file 1: Table S1. Questionnaires used to assess health-related quality of life. Table S2. Compliance rates: FACT-Leu questionnaire. Table S3. Compliance rates: EQ-5D questionnaire. Table S4. Mixed-effects model analysis estimates (idelalisib/placebo) for functional assessment of cancer therapy using FACT-Leu.